Drug Profile
Research programme: antibody therapeutics - Medarex/Xerion
Alternative Names: Antibody therapeutics - Medarex/XerionLatest Information Update: 03 May 2007
Price :
$50
*
At a glance
- Originator Medarex; Xerion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 03 May 2007 No development reported - Preclinical for Undefined indication in Germany (unspecified route)
- 03 May 2007 No development reported - Preclinical for Undefined indication in USA (unspecified route)
- 29 Jun 2005 This programme is still in active development